TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11957809

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinantly produced TNF-α soluble receptor
Number of subjects: 0
Study: 9540875

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate (1:1 mixture with Lipoidol)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sodium tetradecyl sulphate (1.5%)
Number of subjects: 50
Study: 8087526

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study: 2574502

Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Alpidem 75 mg
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 4827071

Group type: EXPERIMENTAL
Intervention: Pharmacological testing in vitro of muscle biopsy specimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7192146

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol retard 160 mg
Number of subjects: 20
Study: 31506252

Group type: EXPERIMENTAL
Intervention: Sacrospinous hysteropexy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension
Number of subjects: 204
Study: 28940737

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF)
Number of subjects: 106

Group type: COMPARATOR
Intervention: NonMetS-OB
Number of subjects: 106

Group type: COMPARATOR
Intervention: NonMetS-NonOB
Number of subjects: 106
Study: 26468683

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23689001

Group type: EXPERIMENTAL
Intervention: Laryngeal mask anesthesia with high-frequency low tidal volume lung ventilation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intubation anesthesia with one-lung ventilation
Number of subjects: 60
Study: 21459942

Group type: EXPERIMENTAL
Intervention: Rehabilitation plus educational-behavioral program (n = 20)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Educational-behavioral program only (n = 20)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 62
Study: 19663523

Group type: EXPERIMENTAL
Intervention: Armodafinil (50, 100, 200, 250, 300 or 400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modafinil (400 mg)
Number of subjects: 0
Study: 17277001

Group type: EXPERIMENTAL
Intervention: Ibandronate (oral or intravenous) at different doses and for variable time intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dose of ibandronate
Number of subjects: 0
Study: 15145173

Group type: EXPERIMENTAL
Intervention: 8 Gy single fraction (SF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 24 Gy in multiple fractions (MF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retreatment overall
Number of subjects: 0
Study: 11267717

Group type: EXPERIMENTAL
Intervention: Uterine lavage
Number of subjects: 25

Group type: COMPARATOR
Intervention: Endocervical lavage
Number of subjects: 25
Study: 9677173

Group type: EXPERIMENTAL
Intervention: Individually focused counselling and skills training intervention including written materials
Number of subjects: 492

Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 492

Group type: COMPARATOR
Intervention: Usual clinic procedure
Number of subjects: 492
Study: 8021734

Group type: EXPERIMENTAL
Intervention: 5 daily 2-hour infusions of 100 mg/m2
Number of subjects: 94

Group type: COMPARATOR
Intervention: 8 daily 75-minute infusions of 62.5 mg/m2
Number of subjects: 94
Study: 2595106

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg over 20 min, followed by 0.9 mg/kg/h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Salbutamol (4 micrograms/kg over 20 min, followed by 3 micrograms/kg/h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aminophylline and Salbutamol
Number of subjects: 7
Study: 4402080

Group type: EXPERIMENTAL
Intervention: Indoramin (20 mg.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoramin (40 mg.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoramin (10 mg.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31356374

Group type: EXPERIMENTAL
Intervention: Sugammadex (SUG group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Neostigmine (NEO group)
Number of subjects: 59
Study: 31647087

Group type: EXPERIMENTAL
Intervention: Daily red wine vinegar ingestion for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 45
Study: 28391435

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-power laser with low dose (30 mW, 10 J/cm2, 9 s per point, 810 nm)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-power laser with high dose (100 mW, 40 J/cm2, 11 s per point, 810 nm)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-power laser with low dose + Gluma Desensitizer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-power laser with high dose + Gluma Desensitizer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1.0 W, 10 Hz, 100 mJ, 1064 nm)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser + Gluma Desensitizer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-power laser with low dose + Nd:YAG laser
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-power laser with high dose + Nd:YAG laser
Number of subjects: 32
Study: 26333366

Group type: EXPERIMENTAL
Intervention: Peripheral G‐CSF combined with IC BMC therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peripheral G‐CSF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peripheral G‐CSF and IC serum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Peripheral placebo (saline)
Number of subjects: 60
Study: 24032424

Group type: EXPERIMENTAL
Intervention: 5 × 10(6) fibroblasts per linear cm of erosion margin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 11
Study: 21876298

Group type: EXPERIMENTAL
Intervention: FES-therapy combined with progressive limb loading
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 61
Study: 19478489

Group type: EXPERIMENTAL
Intervention: Periodontal treatment (PT) during pregnancy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Dental examination for periodontitis (Control group A)
Number of subjects: 83
Study: 16937393

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15051841

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate diet (<10% energy as carbohydrate)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-fat diet (<30% energy as fat)
Number of subjects: 15
Study: 12182772

Group type: EXPERIMENTAL
Intervention: Surgery, external beam radiotherapy, and carmustine (BCNU)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine (BCNU)
Number of subjects: 270
Study: 9440482

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.1 IU/kg daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prednisolone 25 mg morning and evening
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) plus Prednisolone
Number of subjects: 8
Study: 7975785

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. (n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.i.d. (n = 25)
Number of subjects: 50
Study: 2642689

Group type: EXPERIMENTAL
Intervention: Truncal vagotomy and drainage (TV)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Selective vagotomy and drainage (SV)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 248
Study: 1108355

Group type: EXPERIMENTAL
Intervention: Subconjunctival depot corticosteroid
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 30466545

Group type: EXPERIMENTAL
Intervention: CBT + CET
Number of subjects: 102

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 102
Study: 28433211

Group type: EXPERIMENTAL
Intervention: Ketamine monotherapy (KM) 1 mg/kg i.v. (with up to three additional doses of 0.5 mg/kg each)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Co-administration of ketamine and propofol (CoKP) 0.5 mg/kg each i.v. (with up to three additional doses of 0.25 mg/kg each)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Ketamine monotherapy (KM)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Co-administration of ketamine and propofol (CoKP)
Number of subjects: 183
Study: 26054140

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion at 'Xiasanhuang', once a day, with an interval of 2 days after every 10 treatments for 2 months.
Number of subjects: 106

Group type: COMPARATOR
Intervention: Benazepril hydrochloride, 5 to 10 mg orally, once a day for 2 months.
Number of subjects: 106
Study: 23478471

Group type: EXPERIMENTAL
Intervention: SAND (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: GRASS (n = 6)
Number of subjects: 12
Study: 20545545

Group type: EXPERIMENTAL
Intervention: Fresh-frozen bone allograft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autogenous bone (native maxilla)
Number of subjects: 0
Study: 19734172

Group type: EXPERIMENTAL
Intervention: Goshajinkigan (GJG)
Number of subjects: 80
Study: 17409109

Group type: EXPERIMENTAL
Intervention: Carvedilol at a dose of 10-20 mg/day (mean dose: 16 +/- 4 mg/day) for a mean of 12 +/- 1 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 30
Study: 15747470

Group type: EXPERIMENTAL
Intervention: Cefotiam hexetil 200 mg bid over a 5 day period followed by 5 days of placebo
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Cefotiam hexetil 200 mg bid over a 10 day period
Number of subjects: 1042
Study: 11723020

Group type: EXPERIMENTAL
Intervention: CABG with CK-MB measurement
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Patients with increased CK-MB levels after CABG
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Increased CK-MB levels
Number of subjects: 496
Study: 9006357

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal adults (control group)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Patients with hearing loss > 50 dB
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Patients with hearing loss < 50 dB
Number of subjects: 14
Study: 8322791

Group type: EXPERIMENTAL
Intervention: Standard dose OKT3 (5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-dose OKT3 (2 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 3521443

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus amiloride (25 mg hydrochlorothiazide + 2.5 mg amiloride)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone (25 mg)
Number of subjects: 40
Study: 29617633

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (CBT)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Group General Health Education (GHE)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 225

Group type: COMPARATOR
Intervention: Group GHE
Number of subjects: 225
Study: 27381741

Group type: EXPERIMENTAL
Intervention: Semicompeting risks analysis
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Composite endpoints (CEP) analysis
Number of subjects: 1419

Group type: COMPARATOR
Intervention: Univariate analyses for each component endpoint
Number of subjects: 1419
Study: 24188732

Group type: EXPERIMENTAL
Intervention: Asthma self-management educational intervention
Number of subjects: 183

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 183
Study: 22570188

Group type: EXPERIMENTAL
Intervention: Opioid-related adverse effects (specifically constipation, emesis, and confusion)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Patients with two adverse effects
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Patients with three adverse effects
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Patients with four adverse effects
Number of subjects: 402
Study: 20467286

Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (ART)
Number of subjects: 898
Study: 18086314

Group type: EXPERIMENTAL
Intervention: SR stimulation coordination training group (SCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional coordination training group (CCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15857741

Group type: EXPERIMENTAL
Intervention: Active acustimulation wrist band
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham acustimulation wrist band
Number of subjects: 96

Group type: COMPARATOR
Intervention: No acustimulation
Number of subjects: 96
Study: 12147960

Group type: EXPERIMENTAL
Intervention: Aggressive lipid lowering strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate lipid lowering strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive lipid strategy
Number of subjects: 0
Study: 10440141

Group type: EXPERIMENTAL
Intervention: Sotalol (40 patients; mean dose = 190 +/- 43 mg/day)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (45 patients; mean dose = 176 +/- 32 mg/day)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 7558391

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) using washed spermatozoa
Number of subjects: 50

Group type: COMPARATOR
Intervention: LH-timed natural intercourse
Number of subjects: 50
Study: 1599636

Group type: EXPERIMENTAL
Intervention: 5 mg felodipine plus 5 mg enalapril
Number of subjects: 36

Group type: COMPARATOR
Intervention: 10 mg felodipine
Number of subjects: 36

Group type: COMPARATOR
Intervention: 10 mg enalapril
Number of subjects: 36
Study: 3863470

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nomifensine-clobazam
Number of subjects: 40
Study: 31039482

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation for 12 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 181
Study: 30378274

Group type: EXPERIMENTAL
Intervention: 4 mL of hyperosmolar rectal lubricant daily for 7 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily oral TDF/FTC for 7 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both hyperosmolar lubricant and daily oral TDF/FTC for 7 days
Number of subjects: 60
Study: 27687377

Group type: EXPERIMENTAL
Intervention: Ephedrine 2.5mg/min
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Phenylephrine 30μg/min
Number of subjects: 90
Study: 26198931

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Narrative Cognitive Therapy (NCT)
Number of subjects: 97
Study: 23714672

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation combined with transcatheter arterial chemoembolization (RFA + TACE)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Radiofrequency ablation alone (RFA)
Number of subjects: 62
Study: 20301014

Group type: EXPERIMENTAL
Intervention: Policosanols (1 to 20 mg/day)
Number of subjects: 0
Study: 18371559

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Post-randomization syncope
Number of subjects: 564

Group type: COMPARATOR
Intervention: Syncope versus non-syncope patients
Number of subjects: 564
Study: 16634903

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT), 2 treatments, 2 weeks apart
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate-based photodynamic therapy (MAL-PDT)
Number of subjects: 36
Study: 12477710

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11037786

Group type: EXPERIMENTAL
Intervention: CGP 56697 (co-artemether) - 4 x 4 tablets over 48 hours
Number of subjects: 179

Group type: COMPARATOR
Intervention: Chloroquine - 4 tablets initially, followed by two tablets each at 6-8, 24, and 48 hours
Number of subjects: 179
Study: 7543434

Group type: EXPERIMENTAL
Intervention: Screening with alpha‐fetoprotein > or = 20 micrograms/L
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Ultrasonography screening
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Overall cohort screening
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Follow-up screening
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Men only follow-up screening
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Mortality from hepatocellular carcinoma
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Serum alpha‐fetoprotein > 20 micrograms/L
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1069
Study: 2795032

Group type: EXPERIMENTAL
Intervention: Colgen sprinkled around the reduced hip joint after arthroplasty
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no Colgen)
Number of subjects: 76
Study: 626810

Group type: EXPERIMENTAL
Intervention: Ioglycamide infusion at a rate of 4 mg per kg per min for one hour
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ioglycamide infusion
Number of subjects: 15
Study: 31294137

Group type: EXPERIMENTAL
Intervention: KBMSI-2 (6 g twice per day for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28722299

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGB) surgery, N=15
Number of subjects: 745

Group type: COMPARATOR
Intervention: Intensive lifestyle and medical intervention (ILMI), N=17
Number of subjects: 745
Study: 26562602

Group type: EXPERIMENTAL
Intervention: End-of-treatment outcomes (abstinence and good clinical outcome during treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Logistic regression analyses based on good clinical outcome, level of drinking during treatment, age at onset of alcohol dependence, and feeling more energetic
Number of subjects: 0
Study: 23274619

Group type: EXPERIMENTAL
Intervention: Plastic single-use laryngoscope blades
Number of subjects: 1863

Group type: COMPARATOR
Intervention: Metallic reusable laryngoscope blades
Number of subjects: 1863

Group type: COMPARATOR
Intervention: Metallic single-use laryngoscope blades
Number of subjects: 1863
Study: 21469973

Group type: EXPERIMENTAL
Intervention: Drospirenone 2 mg / Estradiol 1 mg (DRSP/E2)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 18341665

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 543

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 543
Study: 16502051

Group type: EXPERIMENTAL
Intervention: Lidocaine gel and povidine iodine lavage
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cephtriaxon and lavage
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 12685672

Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Conventional medical treatments)
Number of subjects: 0
Study: 10752744

Group type: EXPERIMENTAL
Intervention: AT(H) concentrate infusions every 8 hours to raise plasma level to 175% in the first 72 hours after injury
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AT(H) concentrate infusions
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 9
Study: 9373047

Group type: EXPERIMENTAL
Intervention: CO2-enriched water (1000 mg CO2/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fresh water
Number of subjects: 24
Study: 8330548

Group type: EXPERIMENTAL
Intervention: Prophylactic endoscopic sclerotherapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no sclerotherapy)
Number of subjects: 82
Study: 3487938

Group type: EXPERIMENTAL
Intervention: Esophageal radiography using two different air‐contrast techniques
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Esophageal radiography
Number of subjects: 48
Study: 31816432

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 44
Study: 29843811

Group type: EXPERIMENTAL
Intervention: DCVax-L
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard therapy alone (placebo)
Number of subjects: 331
Study: 26919037

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both IA and EA
Number of subjects: 60
Study: 24282101

Group type: EXPERIMENTAL
Intervention: True Moxibustion (TM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham Moxibustion (SM)
Number of subjects: 16
Study: 21609256

Group type: EXPERIMENTAL
Intervention: Single-flap approach (SFA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Double-flap approach (DFA)
Number of subjects: 14
Study: 20090776

Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (CF) 1052 mg day(‐1) for 6 weeks
Number of subjects: 52
Study: 18422916

Group type: EXPERIMENTAL
Intervention: Ketomousse (1% ketoconazole)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ketoconazole cream 2%
Number of subjects: 46
Study: 16187171

Group type: EXPERIMENTAL
Intervention: Methylene blue (3 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 14959904

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 20